[Neurotensin in Itsenko-Cushing disease].
The results are presented on studying the blood neurotensin concentration in 68 patients with Icenko-Cushing's disease and in 5 persons with adrenocortical tumors. Neurotensin fasting content was determined by radioimmunoassay after insulin, glucose, peritol and parlodel administration and following the treatment with chloditane-, chloditane-cyproheptadine complex, a combination of chloditane and a dopaminergic drug. It was found that the blood neurotensin concentration is enhanced in the active stage of Icenko-Cushing's disease. Marked changes were not observed in the blood neurotensin concentration of healthy subjects and patients with Icenko-Cushing's disease under stress, provoked by insulin hypoglycemia and after glucose injection. Different sensitivity to peritol and parlodel was seen in a half of patients with an increased blood neurotensin concentration. During clinical remission of Icenko-Cushing's disease under chloditane and combined chloditane-peritol treatment the blood neurotensin level returned to normal, remaining increased in patients treated with chloditane and a dopaminergic drug.
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000097:blood* / Q000188:drug therapy; D003533:Cyproheptadine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007328:Insulin; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use; D009496:Neurotensin / Q000097:blood*; D013997:Time Factors
D007328:Insulin; D003533:Cyproheptadine; D009496:Neurotensin; D001971:Bromocriptine; D007980:Levodopa; D008939:Mitotane; D002230:Carbidopa
Neĭrotenzin pri bolezni Itsenko-Kushinga.